Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1EU-approved roactemra----[1] 46 💬
2Roactemra[1] Tocilizumab[1] Tocilizumab 💬 [1] IL6R 💬 [11] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[7] 41, 44, 46, 51, 86, 107, 271 💬
3Roactemra - 162 MG - soluzione iniettabile - USO sottocutaneo - siringa preriempita 0,9ML (vetro) - 4 siringhe preriempite[1] Tocilizumab[1] Tocilizumab 💬 [1] IL6R 💬 [11] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[2] 46, 51 💬
4Roactemra - 20 MG/ML concentrato PER soluzione PER infusione - USO endovenoso - flaconcino (vetro) 4ML 1 flaconcino[1] Tocilizumab[1] Tocilizumab 💬 [1] IL6R 💬 [11] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 46 💬
5Roactemra 162 MG[1] Tocilizumab[1] Tocilizumab 💬 [1] IL6R 💬 [11] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[2] 46, 51 💬
6Roactemra 162 MG solution FOR injection IN PRE-filled syringe[1] Tocilizumab[1] Tocilizumab 💬 [1] IL6R 💬 [11] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 41 💬
7Roactemra 162 MG solution injectable EN seringue PRéremplie[1] Tocilizumab[1] Tocilizumab 💬 [1] IL6R 💬 [11] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[2] 46, 56 💬
8Roactemra 162 MG soluzione iniettabile IN siringa preriempita[1] Tocilizumab[1] Tocilizumab 💬 [1] IL6R 💬 [11] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 50 💬
9Roactemra 20 MG/ML concentrado para solucióN para perfusióN[1] Tocilizumab[1] Tocilizumab 💬 [1] IL6R 💬 [11] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 46 💬
10Roactemra 20 MG/ML concentrate FOR solution FOR infusion[1] Tocilizumab[1] Tocilizumab 💬 [1] IL6R 💬 [11] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 46 💬
11Roactemra 20 MG/ML, concentrado para solucióN para perfusióN[1] Tocilizumab[1] Tocilizumab 💬 [1] IL6R 💬 [11] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[3] 46, 107, 271 💬
12Roactemra 20MG/ML[1] Tocilizumab[1] Tocilizumab 💬 [1] IL6R 💬 [11] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 40 💬
13Roactemra® 20MG/ML konzentrat[1] Tocilizumab[1] Tocilizumab 💬 [1] IL6R 💬 [11] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 266 💬
14Roactemra®EV [1] Tocilizumab[1] Tocilizumab 💬 [1] IL6R 💬 [11] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 46 💬